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Summary 
The c-myb protooncogene plays a major role in regulating the process of in vitro and in vivo 
hematopoiesis via its activity as transcriptional regulator in hematopoietic progenitor cells. Since 
the bone marrow microenvironment appears to regulate in vivo hematopoiesis by maintaining 
the growth of multipotent progenitors via secretion of specific cytokines,  we asked whether 
c-myb is also required for the proliferation  of and/or cytokine production by stromal cells that 
generate fibroblast-like colonies (fibroblast colony-forming units [CFU-F]). Using the reverse 
transcriptase polymerase chain reaction technique, we detected low levels  of c-myb mRNA transcripts 
in  human normal bone marrow fibroblasts.  Treatment  of these  cells with c-myb antisense 
oligodeoxynucleotides  caused downregulation of c-myb expression, decrease in the number of 
marrow CFU-F colonies (,x,54% inhibition) and in the cell number within residual colonies 
(~80%), and downregulation of granulocyte/macrophage colony-stimulating factor (GM-CSF) 
and stem cell factor (SCF) mRNA expression. Transfection ofT98G glioblastoma cells, in which 
expression of c-myb, GM-CSF,  and SCF mRNAs is undetectable  or barely detectable, with a 
plasmid containing a full-length c-myb cDNA under the control of the SV40 promoter induced 
the expression of biologically active SCF and GM-CSF in these cells. Regulation of GM-CSF 
expression by c-myb was due in part to transactivation  of the GM-CSF promoter. These results 
indicate that, in addition to regulating hematopoietic cell proliferation,  c-myb is also required 
for proliferation  of and cytokines  synthesis by bone marrow fibroblasts. 
H 
ematopoietic tissue is constantly renewed through the 
proliferation  and differentiation  of stem cells residing 
in the bone marrow in close contact with multiple adherent 
(stromal) cells that comprise the hematopoietic microenviron- 
ment (HM) (1-4). In vitro stromal cells form fibroblast colo- 
nies (CFU-F) that, under defned conditions support long- 
term bone marrow growth of primitive hematopoietic stem 
cells  (long-term  bone  marrow  cultures  [LTBMC] 1  or 
Dexter-type cultures) (1-4). The interactions between the he- 
matopoietic cells and the microenvironment are still poorly 
understood, due to the cellular heterogeneity of this microen- 
vironment and to the difficulties in isolating homogeneous 
populations  of its  components for  genetic and functional 
studies. The development  of the PCR technology has en- 
abled detection of growth factor transcripts in stromal marrow 
fibroblasts, suggesting that, via these cytokines, these cells 
1 Abbreviations used in this  paper: LTBMC, long-term bone marrow culture; 
NBM, normal bone marrow; SCF, stem  cell factor. 
play an important role in hematopoiesis in mammals in vivo 
(5, 6). 
Different experimental  approaches have revealed that the 
protooncogene c-myb plays an important role in regulating 
not only hematopoietic cell growth (7-10), but also prolifera- 
tion of nonhematopoietic cells (11-13). Treatment with synthe- 
tic c-myb antisense oligodeoxynucleotides inhibits formation 
of colonies derived from normal hematopoietic progenitors 
(7-9). Inactivation of the endogenous c-myb gene by homol- 
ogous recombination in mouse embryonic stem cells drasti- 
cally impairs liver hematopoiesis (10). To address the possi- 
bility that c-myb also regulates  stromal  cell function, we 
measured c-myb mRNA levels in bone marrow fibroblasts 
and assessed whether downregulation of c-rnyb expression 
affects proliferation  and cytokine production of these cells. 
Materials and Methods 
Cells and Cell Cultures.  Bone marrow aspirates were obtained 
from the iliac crest of healthy individuals after informed consent. 
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Ficoll/Histopaque density gradient, and centrifuged for 30 min 
at 1,500 rpm. Light-density mononuclear cells were washed in the 
same medium, and plated (5  x  10  s cells/dish)  into 35-mm petri 
dishes (Nunc, Inc., Naperville, IL) in IMDM supplemented with 
15% FCS. After 90 min, supernatant containing nonadherent cells 
was discarded and the remaining adherent cells were cultured. Cul- 
ture medium was  changed every 3 d.  After a 14-d culture, the 
number  of colonies was  counted under  light  microscope after 
staining with 5% crystal violet for 8 min. Cells to be used for KNA 
extraction were grown as monolayers, washed twice with HBSS, 
passaged  four times,  washed with IMDM, and lysed with lysing 
solution directly in the plates. The cell composition of this popula- 
tion of stromal cells was analyzed by surface phenotyping as de- 
scribed below. T98G human glioblastoma cells and TK-ts13 ham- 
ster fibroblasts  (kind gifts  of Drs.  E.  Mercer and R.  Baserga, 
respectively)  were maintained in culture as described (14,  15). 
Indirect Immunofluorescence.  Cells were grown on chamber slides 
(Nunc, Inc.) to subconfluence.  The slides were rinsed with PBS 
and fixed with ice-cold 100% ethanol. After a 30-rain incubation 
with 1% BSA in PBS the samples were exposed to either factor 
VIII (Dako, Denmark), CD14, CDw32, or type I collagen (ICN, 
Costa Mesa, CA) mAbs for 45 min at room temperature. The slides 
were then rinsed with PBS and exposed to rhodamine- or fluo- 
resceine-conjungated anti-mouse IgG mAbs (Cappel Laboratories, 
West Chester, PA) for 45 min. Nonadherent secondary antibodies 
were then washed off with PBS. Nonspecific binding of the anti- 
bodies was excluded by performing controls with secondary anti- 
bodies only. In additional controls, microvascular endothelial cells 
were stained  with antibodies to factor VIII. 
Oligomers and Primers.  These were synthesized on a DNA syn- 
thesizer (308B; Applied Biosystems, Inc., Foster City, CA) by means 
of B-cyanoethyl-phosphorymidite chemistry as described (7). The 
sequences of the c-myb sense and antisense  oligodeoxynucleotides 
used were: 5'-GCC CGA ACA CCC CGG CAC-3' and 5'-GTG 
CCG GGG TCT TGG GGC-3', respectively, c-myb mKNA was 
detected by reverse transcriptase (KT)-PCK amplification of a seg- 
ment ofc-myb mKNA in the 3' untranslated region with a 5' syn- 
thetic primer, 5'-ATT AGG TAA TGA ATT GTA GCC AG-3', 
and a 3' synthetic primer, 5'-ACT TAG AGT AAT GCT TTT ACT 
GA-3'. The amplification product was detected by hybridization 
to the synthetic oligomer included in the amplified fragment (5'- 
ATT TTT TTA AAA AAA AAC ATA AAA TGA TTT ATC 
TAT TTT AAA GGA TCC-Y) encompassing nucleotides 2351- 
2400 of the human c-myb cDNA (16)./3-Actin mKNA levels were 
also analyzed by KT-PCK. The 5' primer corresponds to nucleo- 
tides 224-244; the 3' primer corresponds to nucleotides 411-433 
of/3-actin cDNA. A 39-base probe used to detect the amplification 
product corresponds to nucleotides 258-296 (17). GM-CSF mRNA 
was detected by KT-PCK technique with a pair of synthetic primers: 
5' primer, 5'-ATG TGA ATG CCA TCC AGG AG-3'; 3' primer, 
5'-CTT GTA GTG GCT GGC CAT CA-3' and detected with a 
synthetic probe, 5'-TAG AGA CAC TGC TGC TGA GA-3' (18). 
Stem cell factor (SCF) mKNA was detected using the following 
set of primers: 5' primer, 5'-ATG AAG AAG ACA CAA ACT TGG- 
3'; 3' primer, 5'-GTC CAG AAG ATC AGT CAA GCT-3',  and 
detected by synthetic oligomer probe, 5'-GCC GAG CTG GAC 
AGC ACC GTG CTC CTG ACC CGC TCT CTC-3' (19). 11,6 
mKNA was detected using the following set of primers: 5' primer, 
5'-AAG ATT CAT ACC TCA GAG CG-3'; 3' primer, 5'-ATG AGA 
TCA CCT AGT CCA CC-3'; and detected by synthetic oligomer 
probe, 5'-AGC CCA GAC TCG AAT TCT GGT TCT GCC AAA- 
3'  (20).  I1,11 mRNA  was  detected using  the following set of 
primers:  5' primer,  5'-ATG AAC TGT GTT TGC CGC-3';  3' 
primer, 5'-CCC CTG AGC TGG GAA TTT-3'; and detected by 
synthetic oligomer probe, 5'-GCC GAG CTG GAC AGC ACC 
GTG CTC CTG ACC CGC TCT CTC-3' (21). 
Otigomer Treatment of the Cells.  Normal bone marrow (NBM) 
cells were plated into 35-mm dishes (Nunc, Inc.) in 1 ml IMDM 
1640  supplemented with  15%  FCS.  c-myb sense and  antisense 
oligodeoxynucleotides were added three times during a 14-d cul- 
ture: 40-120/~g/ml, as indicated, was added during the first 18-24 h 
of incubation (37~  5% CO2),  half of the initial dose was added 
on day 3, and a third dose (50% of initial dose) was added on day 
6 after changing the medium. On day 14, the medium was dis- 
carded, the cells were stained  with 5% crystal violet for 8 min, 
and the number of colonies per plate and cell number per colony 
were determined. 
Transfection.  T98G human glioblastoma cells were transfected 
using the calcium-phosphate precipitation method (22). Briefly, 2 
x  10  s cells were either cotransfected with 10/zg of the plasmid 
pMbmI, which contains the human c-myb cDNA under control 
of the SV40 early promoter and enhancer, and 1/~g of the plasmid 
pLHL4, which contains the gene encoding hygromycin resistance 
or transfected with the plasmid pLHL4 only. After 12-d selection 
in  culture  medium  containing  0.5  mg/ml  of hygromycin  B 
(Calbiochem-Behring Corp., San Diego, CA), colonies were pooled 
and cultured in medium containing 0.3 mg/ml of hygromycin B. 
Detection of c-myt~ /~-Actin, GM-CSF, and SCF mRNA Transc@ts 
in Marrow Fibroblasts and in T98G Glioblastoma Ceils.  To analyze 
the effect of c-myb sense and antisense oligodeoxynucleotide treat- 
ment on c-myb expression, 10  s marrow fibroblasts  obtained after 
the fourth passage were plated into 35-mm plastic dishes (Nunc, 
Inc.), and were left untreated or exposed to c-myb sense or antisense 
oligodeoxynucleotides (40 #g/ml at time 0;  20/zg/ml at 24 h); 
24 h later, cells were collected separately from each experimental 
group, before extracting total KNA as described (23,  24). KNA 
from each group was divided into four identical portions, and re- 
verse transcribed using 400 U of Moloney routine leukemia virus 
RT (Bethesda Research Laboratories,  Gaithersburg, MD), and 0.1 
/~g of 3' primers of c-myb,/3-actin,  GM-CSF,  and SCF for 1 h at 
37~  Resulting cDNA fragments were amplified with 5 U of Taq 
polyrrlerase (Perkin-Elmer-Cetus, Norwalk, CT) in the presence 
of 3' and 5' primers generating c-myb,/3-actin, GM-CSF, and SCF 
fragments during 50 cycles of PCK. Amplified DNA was subjected 
to electrophoresis,  transferred to Zetabind nylon filters (Cuno, Inc., 
Meriden,  CT),  and  detected  by  Southern  hybridization  with 
[32p]ATP end-labeled c-myb,/$-actin,  GM-CSF, or SCF synthetic 
probes,  as described (21, 22). Densitometric analysis of hybridiza- 
tion bands was performed using an Ultro Scan XL (Pharmacia LKB) 
apparatus. 
GM-CSF and SCF mKNA levels were determined in 1 #g of 
total RNA derived from parental and SVmyb-transfected T98G cells. 
As positive control for the expression of GM-CSF and SCF, KNA 
derived from PHA-stimulated PBMC and the bladder carcinoma 
HTB9 line,  respectively,  was used.  KNA from each sample was 
divided into four portions, and c-myb, GM-CSF, SCF, and B-actin 
expression was determined by KT-PCK technique. As negative con- 
trol,  RT-PCK amplifications  were performed in  the absence  of 
RNA. 
Detection of GM-CSF and SCF in Cellfree Culture Supernatants 
of SV-myb-transfected T98G Cells.  Cell-free culture supernatants 
were collected from exponentially growing T98G transfected with 
plasmid  pLHL4  encoding  hygromycin resistance  and  SV-myb- 
transfected T98G cells cultured in the presence of 10% FCS. Su- 
pernatants were sterilized by filtration through 0.22-#m filters (Mil- 
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was measured using commercial enzyme immunoassays (R & D 
Systems, Minneapolis, MN), with sensitivity of 1.5 and 3.0 pg/ml, 
respectively. 
Isolation of the 5' Flanking Region of Human GM-CSF Gene and 
Plasmid Construction.  A 600-bp fragment  of the 5' flanking re- 
gion  of the  human  GM-CSF  gene  (18) was  isolated  by PCR 
amplification  of placenta  genomic  DNA  using  the  following 
primers: 5' primer, 5'-AAG CTT GCT GAG AGT GGC TGC-3'; 
3'  primer,  5'-CAG  AGA  ACT  TTA  GCC  TTT  CTC-3'.  The 
amplified fragment  was then  subcloned into the SmaI site of the 
Bluescript vector (Strategene, La JoUa, CA), 5' of the T7 promoter, 
and subjected to sequence analysis to confirm its identity with the 
5' flanking  segment  of the human GM-CSF gene. This plasmid 
was called GMCSF17. A CAT construct  was prepared after diges- 
tion of GMCSF17 with EcoRV and HindlII to isolate the 600-bp 
fragment  and clone it into pucCAT linearized using HindlII and 
SalI restriction  enzymes to obtain the GMCSF fragment in sense 
orientation with respect to the CAT gene. This construct was named 
GM-CSF  CAT2. 
Transient  CAT Analysis.  CAT assays  were performed as described 
(25). Briefly, 2/xg of CAT reporter  plasmid was transfected with 
or without 8 #g of effector plasmid phs 1/~g of pSV-/3-gal, which 
contains the bacterial/3-galactosidase gene driven by the SV40 pro- 
moter as an internal  control of transfection ef~ciency, into wild- 
type or SV-rayb-transfected  Tk-ts13 Syrian hamster fibrobhsts using 
the calcium-phosphate precipitation method (22). 48 h after trans- 
fection,  cells were  harvested  and  proteins  were  extracted  by 
freeze/thawing and normalized for transfection efficiency  by B-gahc- 
tosidase assay as described by the manufacturer  (Promega Biotec, 
Madison, WI). For each assay, cellular lysates were incubated with 
[14C]chloramphenicol and acetyl-CoA for 1 h at 37~  Transacti- 
vation of reporter  constructs  was assayed measuring  the amount 
of acetylated [14C]chloramphenicol by thin-layer chromatography 
followed by autoradiography  and scintillation  counting. 
Results 
Detection of c-myb mRNA  in Bone Marrow Stromal Fibro- 
blasts,  c-myb mRNA  levels  are  relatively  abundant  in 
undifferentiated and proliferating hematopoietic cells but are 
undetectable or present  in few copies in other normal  cell 
types.  To  determine  whether  c-myb mRNA  is  present  in 
marrow stromal fibroblasts and to compare its expression to 
that found in hematopoietic cells, RNA was extracted from 
an equal number of cells from different sources and mRNA 
levels were measured by RT-PCIL analysis (Fig. 1). High levels 
of c-myb mRNA were detected in the myeloid leukemia cell 
line HL 60 (Fig.  1, lane a),  in the Philadelphia 1 lymphoid 
leukemia line BV173 (lane b), in normal marrow mononudear 
cells enriched in early progenitors  (CD34+  cells)  (lane e), 
and in the glioblastoma T98G line transfected with a human 
c-myb cDNA plasmid (SV-myb T98G) (lane at); c-myb mRNA 
levels were barely detectable in WI38 human fibroblasts (lane 
and in the parental T98G cells (lane c); intermediate c-myb 
mRNA levels were detected in marrow  stromal fibroblasts 
(lane g). 
Effect of c-myb Oligoraers on CFU-F Colony Growth.  To 
determine whether cloning efficiency of stromal fibroblasts 
derived from human normal bone marrow depends on c-myb 
expression, the effect of c-myb sense or antisense oligodeox- 
Figure 1.  C-myb  mRNA levels in human hematopoietic and non- 
hematopoietic cells. Total RNA extracted from 5 x  104 HL-60 (lane a), 
BV-173  (lane b), T98G  (lane  c), SV-myb  T98G (lane  d) marrow  mononuclear 
cells enriched in  CD34  + cells (lane e),  WI-38 (lane f),  and human 
marrow stromal fibroblasts (lane g), as described (35), was analyzed by 
RT-PCR for c-rayb and B-actin expression. 
ynucleotides (80 #g/ml at time 0; 40 #g/ml after 24 h), on 
stromal fibroblast colony formation was analyzed in 14-d cul- 
tures.  In four separate experiments, untreated and sense-treated 
cells formed a similar number of colonies,  each containing 
a similar number of cells.  In contrast,  cultures treated with 
c-myb antisense oligodeoxynucleotides showed an "~54% de- 
crease in colony number and an '~80%  decrease in cell con- 
tent  per colony (Table  1).  Fig.  2 illustrates  these effects in 
a representative  experiment. 
Effect of  c-myb Antisense Oligonucleotides  on c-myt~ GM-CSF, 
and  SCF  mRNA  Levels in  Stromal Cells.  To  determine 
whether the inhibition of stromal fibroblasts colony forma- 
tion  was associated with  downregulation  of c-myb expres- 
sion, c-myb mRNA levels were determined by RT-PCR after 
exposure of stromal cells collected after the fourth passage, 
to c-myb sense or antisense  oligodeoxynucleotides. These cells 
showed an intense staining for type I collagen, and were nega- 
tive for the expression of factor VIII,  CD14,  and  CDw32 
normally expressed by endothelial cells and megakaryocytes, 
and by monocyte/macrophages respectively.  These results and 
the characteristic morphology of the cells indicate that  the 
culture consisted of fibroblasts only, in agreement with a pub- 
lished study (6). c-myb mRNA expression was easily detected 
at similar levels in untreated (Fig. 3 a) and sense-treated stromal 
cells  (Fig.  3  b),  whereas  significantly lower c-myb mlkNA 
levels were present in cells treated with c-myb antisense oli- 
gonucleotides (Fig.  3 c). Densitometric measurement of the 
c-myb hybridizing bands in sense-vs.-antisense  oligodeoxynu- 
cleotide-treated  samples indicated  that  the  signal from the 
antisense-treated samples was <10% of that from the sense- 
treated  sample. 
To  determine  whether  inhibition  of  c-myb expression 
affected stromal fibroblast cell functions, we investigated GM- 
CSF, SCF, IL-6, and IL-11  mRNA levels in c-myb sense- or 
antisense-treated cultures in four different experiments. High 
levels  of GM-CSF and SCF mRNAs were detected in un- 
treated and c-myb sense-treated cultures (Fig. 3, lanes a and 
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Exp. 
1  2  3  4 
Control 
Colony No.  14.4  _+  2*  34.5  +  3.5  16.7  _+  2.3  26.8  _+  6.8 
Cells/colony  1718.5  _+  127.3  500  +  50.9  1781  _+  88.1  110.3  +  41.7 
Sense 
Colony no.  17.5  _+  0.7  47.08  _+  2.8  13.5  _+ 0.7  31  _+  4.2 
Cells/colony  1843  _+  391.2  578.5  _+  44.5  1408.3  _+  218.2  65  _+  19.3 
Antisense 
Colony no.  7.5  _+  2.1  17.7  +  1.5  7.01  _+  1.4  16.25  _+  3.4 
Cells/colony  327.3  _+  40.2  90.3  +  32  309.2  _+  47.3  20.2  _+  5.9 
Percent inhibition 
Colony growth*  57.2  62.4  48.7  47.5 
(significance)  p <0.001  /, <0.002  p <0.005  p <0.03 
Percent inhibition 
Cells/colonyS  82.2  84.3  78.8  68.9 
(significance)  p <0.001  p <0.005  p <0.005  p <0.015 
* Data are mean _+ SD from quadruplicate plates. 
* Calculated from the ratio between colony number in sense- and antisense-treated cultures. 
S  Calculated from the ratio of number of cells/colony  (10 for each group) in sense- and antisense-treated  cultures. 
b), whereas these were reduced by >90% in cultures exposed 
to c-myb antisense oligodeoxynucleotides (Fig.  3,  lanes c). 
In contrast, IL-6 and IL-11 mRNA levels were not affected 
by the treatment with c-myb antisense oligodeoxynucleotides 
(not shown). IL-3 mRNA levels, barely detectable in stromal 
cells, were not modified in cultures treated with c-myb an- 
tisense oligodeoxynucleotides (not shown). Levels of B-actin 
mRNA, used as control, were constant. 
Expression of GM-CSF and SCF in T98G Cells Constitu- 
tively Expressing c-myh  To further investigate whether c-myb 
expression is linked to that of GM-CSF and SCF, T98G glio- 
blastoma cells, which express undetectable or low levels of 
endogenous c-myb, were transfected with a human c-myb 
cDNA driven by the SV40 promoter in the presence of the 
plasmid carrying the gene encoding hygromycin resistance. 
After selection, a mixed cell population of T98G cells trans- 
fected with a human c-myb cDNA driven by the early SV40 
promoter (SV-m~,b T98G) (Fig. 4, lane b) and expressing the 
exogenous c-myl~ at high levels appeared  to express higher 
levels of GM-CSF or SCF mRNA compared with T98G cells 
transfected  only  with  the  plasmid  pLHL4  encoding 
hygromycin resistance (Fig. 4, lane a). In SV-myb T98G cells 
the level of expression of  GM-CSF and SCF mRNAs increased 
linearly with increase in the number of PCR cycles from 30 
to 50 (not shown). Consistently, we were unable to detect 
SCF mRNA in control T98G cells, whereas GM-CSF mRNA 
could be detected only after as many as 50 cycles of PCR 
amplification (not  shown).  In  SV-myb  T98G  cells,  SCF 
mRNA levels appeared  essentially identical to those found 
in HTB9 cells, whereas GM-CSF mRNA levels  were less abun- 
dant than in PHA-stimulated PBMC. GM-CSF and SCF levels 
were measured in the cell-free culture supernatant from the 
control and the SV-myb-transfected T98G cells. A 3-4- and 
a 10-14-fold increase in secreted GM-CSF and SCF proteins, 
respectively,  was detected in SV-myb T98G cells, compared 
with T98G cells transfected only with plasmid pLHL4 (Fig. 
5). Biological activity of the secreted cytokines was analyzed 
using the acute myelogenous leukemia MO7 cell line, whose 
proliferation is dependent on exogenously added IL-3, GM- 
CSF,  or SCF  (26-28).  Either  104 or  105  MO7 cells were 
seeded on a feeder layer of exponentially growing control or 
SV-myb-transfected  T98G cells and the number of cells in 
suspension was counted at different days. MO7 cells seeded 
on  the  feeder  layer  of SV-myb  T98G  cells  continued  to 
proliferate over a 5-d period. In contrast, T98G cells trans- 
fected only with plasmid pLHL4 encoding hygromycin re- 
sistance were not able to support the growth of MO7 cells 
(Fig.  6).  T98G cells are growth arrested  when they reach 
confluence (14, 29,  and our own observations);  to exclude 
the possible  presence  of contaminating T98G cells among 
MO7-growing cells, expression  of CD45, present on MO7 
cells and absent on SV-myb T98G cells, was analyzed by flow 
cytometry  in the cells growing in suspension. More than 90% 
of the cells were CD45 + (data not shown), thus confirming 
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oligodeoxynucleotides on  human  CFU-F 
NBM  colony formation.  (Left) Effect of 
c-rayb  oligomers on the number of CFU-F 
colonies  from NBM cells. The corresponding 
higher magnification  pictures (right)  show the 
effect of c-rayb  oligomers on CFU-F colo- 
nies cellularity. (A) Untreated cultures; (S) 
c-rayb sense-treated cultures;  (AS) c-myb 
antisense-treated cultures. 
the proliferation of MO7 cells on the feeder layer of SV-myb 
T98G cells. 
c-myb Transactivation  of CAT Gene Expression Driven by the 
Human GM-CSF 5' Flanking Region Containing Putative Myb 
Binding Sites.  To assess  the ability of c-myb to transactivate 
GM-CSF,  transient expression assays  were performed using 
a CAT reporter construct containing a 600-bp fragment of 
the human GM-CSF 5' flanking region found to contain sev- 
eral putative Myb binding sites. In Tk-ts13 hamster cells trans- 
fected at  a  5:1 E/T ratio and  assayed 48  h  later,  the SV40 
c-myb effector plasmid induced a fivefold increase in CAT ex- 
pression driven by the 600-bp GM-CSF 5' flanking segment 
(Fig. 7 A); a similar level of transactivation of the GM-CSF 
5' flanking sequence was found in SV-myb-Tk-ts13 cells con- 
stitutively expressing a human c-myb cDNA (Fig. 7 B, lane 2). 
These  latter  cells  were  also  transfected  with  the  GM- 
CSFCAT2 construct in the presence of an excess (100:1,  molar 
ratio) of a 22-base synthetic oligomer containing two canon- 
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Figure 3.  Effect  of c-m,/b antisense  oligodec0o/nudeotides 
on c-myb  GM-CSF  and SCF mR,NA  levels  in human marrow 
stromal fibroblasts. (Lanes a)  Untreated  cells; (lanes b) 
c-nr),b  sense-treated  cells; and (lanes  c) c-raTb  antisense-treated 
cells. As control, ~-actin mRNA expression  was evaluated 
in each sample. Identical qualitative results were obtained 
with 30 or 40 KT-PCR amplification cycles. Figure  4.  Expression  of c-myb,  GM-CSF, 
and  SCF  in  T98G  and  SV-mTb T98G  cells. 
RNA  extracted  from:  (lanes  a)  T98G  glio- 
blastoma cells,  (lanes  b) SV-myb  T98G  cells, 
(lanes c) PHA-stimulated PBMC (GM-CSF), 
and HTB cells (SCF)  was analyzed by IkT-PCR 
for c-myb, GM-CSF,  and SCF expression. As 
control,/5-actin  mRNA  expression was ana- 
lyzed in all samples. 
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two independent  experiments. (O) GM-CSF  or SCF  standard (pg/ml); 
(i)  GM-CSF  or SCF  detected in  supernatant  (pg/ml). 
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Figure  6.  Proliferation  of  MO7  cells  upon  coculture  with  c-rayb- 
transfected T98G cells.  MO7 cells (104 or 105, as indicated)  were added 
to 80%  confluent  monolayers of adherent  T98G  cells transfected  with 
pLHL4 (hygromycin resistance  gene) (O) or cotransfected  with pLHL4 
and pMbml (c-rayb  driven by the SV-40 promoter) (0).  The number of 
cells growing  in  suspension  was counted at  the indicated  times. 
1002  c-myb and the Bone Marrow  Microenvironment Figure 7.  c-rayb  transactivation of the human GM-CSF promoter in 
Tk-ts 13 hamster fibroblasts.  (A) Autoradiogram shows CAT activity in 
lysate  of Tk-ts13 cells transfected  with:  (lane  I) GM-CSF CAT 2 only; 
(lane 2) GM-CSF CAT 2 and pMb ml (human c-myb  cDNA driven by 
the SV 40 promoter).  (B) Autoradiogram shows CAT activity in lysate 
of:  (lane I) Tk-ts13 cells transfected  with GM-CSF CAT 2; (lane 2) SV- 
myb Tk-ts13 cells transfected  with GM-CSF CAT 2; (lane 3) SV-myb  Tk- 
ts13 cells transfected with GM-CSF CAT 2 plus a 22-base synthetic oligomer 
containing  two Myb binding  sites;  (lane 4) SV-rayb  Tk-ts13 cells trans- 
fected with GM-CSF CAT 2 plus a 22-base synthetic oligomer containing 
mutated (three nucleotide substitutions) Myb binding sites. (C) Autora- 
diogram shows CAT activity in lysate of: (lane 1) Tk-ts13 cells transfected 
with pSVoCAT (5 mg); (lane 2) Tk-ts13 cells transfected  with pSV-CAT 
plus a 22-base synthetic oligomer containing two Myb binding sites. (Bottom) 
Scintillation  counting  of acetylated [14C]chloramphenicol. 
ical Myb binding sites or a 22-base synthetic oligomer with 
mutations at both sites. Transactivation of the GM-CSF CAT2 
construct in the transfected cells was abolished by the wild 
type 22-mer competitor, but was unaffected by the mutated 
competitor (Fig. 7 B, lanes 3 and 4), suggesting that the trans- 
activation of the GM-CSF promoter directly depended on 
c-myb expression and interaction with Myb binding sites. 
To demonstrate that the 22-base oligomer containing two 
canonical Myb binding sites was nontoxic, CAT activity was 
analyzed in Tk-tk13 cells transfected  with pSV-CAT in the 
presence (Fig. 7 C, lane 2) or in the absence (Fig. 7 C, lane 
I)  of excess amount (100:1, molar ratio)  of the synthetic 
oligomer. Levels of CAT activity were identical, confirming 
the specificity of the effects observed. 
Discussion 
We have recently shown that the product of c-myb plays 
an important role in normal and leukemic hematopoiesis, per- 
haps by directly regulating the proliferation of normal early 
hematopoietic progenitors and leukemic cells. The role of 
c-myb  does not appear to be restricted to hematopoietic cells, 
since other normal and neoplastic nonhematopoietic  cells ex- 
pressing c-myb require this gene for proliferation (11-13). 
Because normal bone marrow contains nonhematopoietic 
adherent progenitor cells (CFU-F) capable of forming fibro- 
blast colonies that support long-term growth of hemopoietic 
stem cells in vitro, we investigated whether c-myb  is expressed 
in these cells and whether it is important for their prolifera- 
tion and function. Downregulation of c-myb expression  in 
marrow stromal cells was associated with inhibition of colony 
formation derived from CFU-F progenitors (',~54%, inhibi- 
tion of colony formation) and with a reduced number of cells 
in each residual colony (~80% reduction), suggesting that 
the relatively low levels of c-myb  expression in these cells were 
nevertheless important for their proliferation. Marrow fibro- 
blasts  appear to express c-myb  mRNA at levels lower than 
those  of  normal  or  leukemic  hematopoietic  cells  but 
significantly higher than those found in the WI-38 human 
fibroblasts,  cells considered to be negative for c-myb  expres- 
sion. In agreement with our findings, low-level expression 
of c-myb  in murine fibroblasts  and requirement of c-myb  for 
Gt/S transition in these cells has recently been shown (30). 
The limited effect of c-myb antisense oligodeoxynucleotide 
on marrow fibroblast  proliferation may reflect the require- 
ment by these cells of the function of other members of the 
myb gene family, such as B-myb,  which we have recently shown 
to behave as a c-myb  functional equivalent in fibroblasts (31). 
Nevertheless,  the findings reported here provide additional 
evidence that the role of c-myb is more general than previ- 
ously thought and are consistent with similar findings in other 
nonhematopoietic systems, such as that of colon carcinoma 
and  neuroblastoma cell  proliferation and  normal  smooth 
muscle cell proliferation (11-13). 
To further investigate the relevance ofc-myb  expression for 
stromal fibroblast cell function, we assessed whether cytokine 
production was regulated by c-rayb.  Several lines of evidence 
support this hypothesis: (a) downregulation ofc-myb expres- 
sion in stromal fibroblasts  was associated with a specific de- 
crease in GM-CSF and SCF mKNA levels; (b) constitutive 
expression of c-myb in a glioblastoma cell line with low or 
undetectable levels of endogenous c-myb  was associated with 
upregulation of GM-CSF and SCF mRNAs and proteins; 
and (c) c-myb  transactivated  the expression of a reporter gene 
driven by a segment of the 5' flanking region of the human 
GM-CSF gene. Although we cannot exclude that downregu- 
lation of GM-CSF and SCF expression in marrow fibroblasts 
exposed to c-myb  antisense oligodeoxynucleotides  is, at least 
in part, a consequence of the growth inhibition of these cells, 
the observation that GM-CSF and SCF expression is upregu- 
lated in T98G cells whose growth is independent of c-myb 
expression, and that c-myb has a direct effect on the GM- 
CSF promoter, makes it  unlikely that GM-CSF  and SCF 
1003  Szczylik  et al. production are solely related to proliferative effects. The pos- 
sible involvement of c-myb in regulating  the expression of 
hematopoietic growth factors is not completely surprising 
in light of the recent observation of selective upregulation 
of insulin-like growth factor 1 (IGF-1) expression in murine 
fibroblasts constitutively expressing c-myb (32).  The signi- 
ficance of the functional link between c-myb and hematopoi- 
etic growth factors may not be restricted to marrow fibro- 
blasts; a subset of primary leukemic cells expresses GM-CSF 
(33, 34). Perhaps the overexpression of c-myb often observed 
in leukemic cells leads to autocrine cytokine expression that, 
in turn, contributes to the growth advantage of leukemic cells. 
In summary, c-myb appears to play a role in regulating both 
proliferation and cytokine production in marrow fibroblasts. 
Although the mechanisms involved in this function remain 
unknown, our findings underscore the importance of the role 
ofc-myb in the regulation of  cell  physiology and suggest poten- 
tial consequences of c-myb activation in hematological malig- 
nancies. 
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